Zicom Group invests in Singapore growth phase medtech Histoindex

Story by Proactive Investors

Zicom Group and Singapore Government agency SPRING Singapore will jointly make their first investment of S$2 million (A$1.9 million) into growth phase medtech start-up Histoindex Pte Ltd.

Histoindex’s state-of-the-art technology is focused on imaging and quantitative analysis of unstained liver tissues for liver fibrosis and cancers which can enable personalised treatment.

The technology has been validated by more than 2,000 patients in China, Europe and U.S. and can be expanded to cover multi-organs as part of its technology road map.

The joint venture is developing a Liver Cloud to digitize the technology as a platform to integrate the entire potential Chinese market that is made up of patients, hospitals, healthcare institutions, research institutes, pharmaceutical suppliers and potentially developing it into an on-line transactional medium for the various users.


Our site uses cookies or similar technologies to recognise your repeated visits and preferences for us to deliver an optimal browsing experience. Please remember to read our privacy statement.

By clicking on "I Accept" or "X" to continue your browsing on this site, you consent to the use of the cookies. To find out how you can disable cookies on your device, please click here.

I Accept